Literature DB >> 26279424

Tempol, a Superoxide Dismutase-Mimetic Drug, Ameliorates Progression of Renal Disease in CKD Mice.

Wei Ding1, Bin Wang, Minmin Zhang, Yong Gu.   

Abstract

BACKGROUND: Oxidative stress has been implicated in the pathogenesis of chronic kidney disease (CKD) and antioxidants may ameliorate disease progression. We investigate the beneficial effect of Tempol, a superoxide dismutase-mimetic drug, on progression of disease in a mouse model of CKD.
METHODS: CKD was surgically induced in c57BL/6 mice by 5/6 nephrectomy. Mice were randomly divided into 3 groups: sham group, 5/6 nephrectomized group (Nx) and Nx+Tempol (2 mmol/l in drinking water). Mice were sacrificed at the end of 12 weeks. Renal function, structure as well as expression of key molecules involved in the pathogenesis of inflammation, fibrosis and progression in mice were measured.
RESULTS: Reduced body weight and impaired renal function (elevation on serum creatinine, blood urea nitrogen, urine albumin, segmental sclerosis and tubulointerstitial damage) was demonstrated in Nx mice but was significantly improved by Tempol administration. Nx animals exhibited significantly elevated proinflammatory and profibrotic factors, activation of NF-κB, increased expression of NADPH oxidase related subunits (p47phox, p67phox, gp91phox), and elevated activation of TGF-β/Smad3, EGFR, MAPK signaling pathway. Tempol inhibited NF-κB mediated inflammation, TGF-β/Smad3-induced renal fibrosis as well as EGFR and MAPK signaling pathway activation.
CONCLUSIONS: Tempol administration attenuated renal injury in CKD mice through NF-κB, TGF-β/Smad3, redox-senstive EGFR activation and c-Raf/MEK/ERK pathways.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26279424     DOI: 10.1159/000430183

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  10 in total

Review 1.  Stop chronic kidney disease progression: Time is approaching.

Authors:  Usama Abdel Azim Sharaf El Din; Mona Mansour Salem; Dina Ossama Abdulazim
Journal:  World J Nephrol       Date:  2016-05-06

2.  Deletion of UCP1 enhances ex vivo aortic vasomotor function in female but not male mice despite similar susceptibility to metabolic dysfunction.

Authors:  Nathan C Winn; Zachary I Grunewald; Michelle L Gastecki; Makenzie L Woodford; Rebecca J Welly; Stephanie L Clookey; James R Ball; T'Keaya L Gaines; Natalia G Karasseva; Jill A Kanaley; Harold S Sacks; Victoria J Vieira-Potter; Jaume Padilla
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-06-27       Impact factor: 4.310

Review 3.  Oxidative stress in chronic kidney disease.

Authors:  Kristien Daenen; Asmin Andries; Djalila Mekahli; Ann Van Schepdael; François Jouret; Bert Bammens
Journal:  Pediatr Nephrol       Date:  2018-08-13       Impact factor: 3.714

4.  Endoplasmic Reticulum Chaperon Tauroursodeoxycholic Acid Attenuates Aldosterone-Infused Renal Injury.

Authors:  Honglei Guo; Hongmei Li; Lilu Ling; Yong Gu; Wei Ding
Journal:  Mediators Inflamm       Date:  2016-09-19       Impact factor: 4.711

5.  NLRP3 Deficiency Attenuates Renal Fibrosis and Ameliorates Mitochondrial Dysfunction in a Mouse Unilateral Ureteral Obstruction Model of Chronic Kidney Disease.

Authors:  Honglei Guo; Xiao Bi; Ping Zhou; Shijian Zhu; Wei Ding
Journal:  Mediators Inflamm       Date:  2017-02-28       Impact factor: 4.711

6.  Factor Xa inhibitor, edoxaban ameliorates renal injury after subtotal nephrectomy by reducing epithelial-mesenchymal transition and inflammatory response.

Authors:  Lixin Fang; Koji Ohashi; Hayato Ogawa; Naoya Otaka; Hiroshi Kawanishi; Tomonobu Takikawa; Yuta Ozaki; Kunihiko Takahara; Minako Tatsumi; Mikito Takefuji; Toyoaki Murohara; Noriyuki Ouchi
Journal:  Physiol Rep       Date:  2022-03

Review 7.  Kidney Injuries and Evolution of Chronic Kidney Diseases Due to Neonatal Hyperoxia Exposure Based on Animal Studies.

Authors:  Liang-Ti Huang; Chung-Ming Chen
Journal:  Int J Mol Sci       Date:  2022-07-31       Impact factor: 6.208

8.  Protective effects of hydrogen sulfide on chronic kidney disease by reducing oxidative stress, inflammation and apoptosis.

Authors:  Hassan Askari; Behjat Seifi; Mehri Kadkhodaee; Nima Sanadgol; Mohammed Elshiekh; Mina Ranjbaran; Parisa Ahghari
Journal:  EXCLI J       Date:  2018-01-02       Impact factor: 4.068

9.  Glycaemic control in type 2 diabetic patients with chronic kidney disease: the impacts on enzymatic antioxidants and soluble RAGE.

Authors:  Foo Nian Wong; Kek Heng Chua; Jin Ai Mary Anne Tan; Chew Ming Wong; Umah Rani Kuppusamy
Journal:  PeerJ       Date:  2018-03-30       Impact factor: 2.984

Review 10.  Superoxide Dismutase Administration: A Review of Proposed Human Uses.

Authors:  Arianna Carolina Rosa; Daniele Corsi; Niccolò Cavi; Natascia Bruni; Franco Dosio
Journal:  Molecules       Date:  2021-03-25       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.